Sunday, July 11, 2004

Acomplia - The New Obesity Treatment

Acomplia - The New Obesity Treatment

The revolutionary weight-loss drug.

Grays, Essex (PRWEB) July 20, 2006

All of us need and have fat tissue in our bodies. However, when there is too much body fat, the result is obesity. Obesity is a complex multifactorial chronic disease that develops from an interaction of geno-type and the environment. Obesity develops because of social, behavioral, cultural, physiological, metabolic and genetic factors.

Obesity is a chronic disease with a strong familial component;

Obesity increases the risk of developing health related risks like high blood pressure, diabetes (type 2), heart disease, stroke, gallbladder disease and cancer of the breast, prostate and colon.

Health insurance companies rarely pay for obesity treatment despite its serious effects on health.

The tendency toward obesity is often due to our environment: lack of physical activity combined with high-calorie, low-cost foods.

If maintained, even weight loss as small as 10 percent of body weight can improve one's health.

Aim for a healthy weight and fight obesity:-

If you are overweight or obese, carrying this extra weight puts you at risk for developing many diseases, especially heart disease, stroke, diabetes, and cancer.

Losing this weight helps to prevent and control these diseases. You can shed weight safely and in a fast way with Prescription Diet Pills.

Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the United Kingdom, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans. The drug, which will be marketed in Europe as Acomplia, ultimately is expected to reach the United States market under the name Zimulti.

Whatever the trade name, rimonabant has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.

Sanofi's highly-anticipated diet pill Acomplia (rimonabant) was formally launched on June 28th in Britain with the announcement that the diet drug can be purchased by patients who obtain a prescription from a general practitoner.

Rxchemist is one of UKs leading online pharmacy retailers, having dispensed over 250,000 prescriptions from their facility capable of dealing with 1000 prescriptions daily.